Amorolfine tidy-up sharpens Kyorin's strategic focus
This article was originally published in Scrip
Executive Summary
As part of an ongoing effort to concentrate on its main areas of therapeutic focus, Kyorin Holdings is transferring its remaining interests in amorolfine to partner Galderma.